Preventive antibiotics in pediatric patients with acute myeloid leukemia (AML)

Pediatric Blood and Cancer

Volumn 62, Issue 7, 2015, Pages 1149-1154

  Nolt, Dawn ^a   Lindemulder, Susan ^a   Meyrowitz, Jeffrey ^a   Chang, Bill H ^a   Malempati, Suman ^a   Thomas, Gregory ^a   Stork, Linda ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

AML; Fever; Neutropenia; Preventive

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CEFEPIME; CEFTAZIDIME; FLUCONAZOLE; MICAFUNGIN; VANCOMYCIN; VORICONAZOLE; ANTIINFECTIVE AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; DEATH; DISEASE COURSE; ELECTRONIC MEDICAL RECORD; FEASIBILITY STUDY; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; MEDICAL RECORD REVIEW; NEUTROPENIA; NEUTROPHIL COUNT; OPPORTUNISTIC INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; PULMONARY CANDIDIASIS; QUALITY CONTROL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SAFETY; STREPTOCOCCUS VIRIDANS INFECTION; CANCER STAGING; COMPLICATION; FOLLOW UP; INFANT; MICROBIOLOGY; NEWBORN; OPPORTUNISTIC INFECTIONS; PROGNOSIS;

ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM STAGING; OPPORTUNISTIC INFECTIONS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84929359566     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25463     Document Type: Article

References (19)

1. Lehrnbecher T, Varwig D, Kaiser J, Reinhardt D, Klingebiel T, Creutzig U. Infectious complications in pediatric acute myeloid leukemia: Analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 2004; 18:72-77.
2. Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood 2007; 110:3532-3539.
3. Sung L, Aplenc R, Alonza TA, Gerbing RB, Meshinchi S, Burden L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Wallas T, Smith FO, Gamis AS. Severe toxicities during pediatric acute myeloid leukemia chemotherapy: A report from the Children's Oncology Group. Blood (ASH Annual Meeting Abstracts) 2010; 116:1071.
4. Sung L, Aplenc R, Alonzo TA, Gerbing RB, Lehrnbecher T, Gamis AS. Effectiveness of supportive care measures to reduce infections in pediatric AML: A report from the Children's Oncology Group. Blood 2013; 121:3573-3577.
5. Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, DeGraaf SS, Harrison CJ. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 12:2130-2138.
6. Centers for Disease Control and Prevention. Multidrug-resistant organism & Clostridium difficile infection (MDRO/CDI) module. http://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf. Accessed February 10, 2015.
7. DePauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-1821.
8. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-281.
9. Inaba H, Gaur AH, Cao X, Flynn PM, Pounds SB, Avutu V, Marszal LN, Howard SC, Pui CH, Ribeiro RC, Hayden RT, Rubnitz JE. Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. Cancer 2014; 120:1985-1992.
10. Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ, Feusner J, Iannone R, Lavey RS, Meshinchi S, Gamis A. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the Children's Oncology Group. Cancer 2012; 118:761-769.
11. Kurt B, Flynn P, Shenep JL, Pounds S, Lensing S, Ribeiro RC, Pui CH, Razzouk BI, Rubnitz JE. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer 2008; 113:376-382.
12. Feng X, Ruan Y, He Y, Zhang Y, Wu X, Liu H, Liu X. Prophylactic first-line antibiotics reduce infectious fever and shorten hospital stay during chemotherapy-induced agranulocytosis in childhood acute myeloid leukemia. Acta Haematol 2014; 132:112-117.
13. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JH, Wingard JR. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:93.
14. Lehrnbecher T, Phillips R, Alexander S, Alvaro F, Carlesse F, Fisher B, Hakim H, Santolaya M, Castagnola E, Davis BL, Dupuis LL, Gibson F, Groll AH, Gaur A, Gupta A, Kebudi R, Petrilli S, Steinbach WJ, Villarroel M, Zaoutis T, Sung L. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol 2012; 30:4427-4438.
15. Children's Oncology Group. Levofloxacin in preventing infection in young patients with acute leukemia receiving chemotherapy or undergoing stem cell transplantation. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). http://www.clinicaltrials.gov/ct2/show/NCT01371656 NLM Identifier: NCT01371656. Accessed February 10, 2015.
16. Cornely OA, Wicke T, Seifert H, Bethe U, Schwonzen M, Reichert D, Ullmann AJ, Karthaus M, Breuer K, Salzberger B, Diehl V, Fatkenheuer G. Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: A randomized controlled multicenter trial in patients with febrile neutropenia. Int J Hematol 2004; 79:74-78.
17. Burgess DS, Hall RG, Hardin TC. In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2003; 46:131-137.
18. Garrison MW. Pharmacodynamic assessment of the activity of high dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2006; 54:51-56.
19. de Blank P, Zaoutis T, Fisher B, Troxel A, Kim J. Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer. J Pediatr 2013; 163:699-705.